Neuroendocrine tumors
Neuroendocrine tumors are rare, accounting for less than 1% of all malignant tumors, and most occur in the stomach, intestines, and pancreas. The most common of these tumors is carcinoid, with an incidence of approximately 2.5/100,000, accounting for 50% of all gastrointestinal and pancreatic neuroendocrine tumors. Depending on the site of origin, carcinoids can be divided into the foregut (lungs, bronchi, and upper gastrointestinal tract up to the jejunum), midgut (ileum and appendix), and hindgut (rectum and rectum). This type of tumor can occur throughout the neuroendocrine system, but the most common site of involvement is the pancreas. Neuroendocrine tumors can be divided into two major categories based on whether the substances secreted by the tumor cause typical clinical symptoms - functional and non-functional.
-
Site of disease:
Cranial peripheral nervous system Other -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
Chapped lips capillary dilation painful red tongue thrombocytopenia skin redness and swelling -
Concurrent disease:
Related Drugs
Fludarabine phosphate
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Manufacturer:
Nanjing Hairun Pharmaceutical Co., Ltd.
Fludarabine Phosphate for Injection
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Lanreotide Acetate for Injection
Indication: 1. Active acromegaly, including patients whose serum GH level does not reach normal level after surgery for pituitary GH tumors, and after external pituitary irradiation radiotherapy. 2. Patients whose serum GH level is still elevated before the full therapeutic effect is achieved, and before surgery for pituitary tumors in some cases. 3. Severe diarrhea, flushing, electrolyte imbalance, exudative polymorphic rash caused by gastrointestinal neuroendocrine tumors and carcinoid syndrome, and AIDS-related diarrhea.
Lanreotide Acetate for Injection
Indication: 1. Active acromegaly, including patients whose serum GH level does not reach normal level after surgery for pituitary GH tumors, and after external pituitary irradiation radiotherapy. 2. Patients whose serum GH level is still elevated before the full therapeutic effect is achieved, and before surgery for pituitary tumors in some cases. 3. Severe diarrhea, flushing, electrolyte imbalance, exudative polymorphic rash caused by gastrointestinal neuroendocrine tumors and carcinoid syndrome, and AIDS-related diarrhea.
Octreotide acetate
Indication: This product is only suitable for acromegaly and some digestive tract carcinoids and neuroendocrine tumors that require long-term administration. It is not suitable for short-term treatment of acute pancreatitis, upper gastrointestinal bleeding, etc.
Manufacturer:
Hainan Zhonghe Pharmaceutical Co., Ltd.
Fludarabine Phosphate for Injection
Indication: For the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not improved or has progressed during or after treatment with at least one standard alkylating agent-containing regimen.
Manufacturer:
Chongqing Lummy Pharmaceutical Co., Ltd.
KIT FOR THE PREPARATION OF INDIUM IN 111 PENTETREOTIDE- indium in-111 pentetreotide
Indication: Indium In 111 pentetreotide injection, after radiolabeling is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
Manufacturer:
Sun Pharmaceutical Industries, Inc.